xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Amazon Explores AI Content Marketplace With Media Publishers 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present at four upcoming Investor Conferences.
2018 RBC Capital Markets Global Healthcare Conference
Date: Thursday, February 22, 2018
Presentation: 8:00-8:25 AM ET
Webcast available under Investor Relations tab at CRISPRTx.com
Barclays Global Healthcare Conference
Date: Tuesday, March 13, 2018
Presentation: 3:20-3:45 PM ET
Guggenheim Conference on Disruptive Technologies in Immuno-Oncology
Date: March 27th, 2018
17th Annual Needham Healthcare Conference
Date: March 28th, 2018
Presentation: 3:30 PM ET
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.
MEDIA CONTACT:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 [email protected]
INVESTOR CONTACT:
Chris Erdman
+1 617.307.7227 [email protected]
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 [email protected]
